A new policy shift by the Trump administration has altered the approval process for annual COVID-19 shots, restricting them for healthy younger adults and children. The FDA outlined a framework that focuses on high-risk groups, such as adults aged 65 and older and younger individuals with health issues. This shift necessitates extensive studies for vaccines aimed at healthier populations, raising concerns about accessibility and insurance coverage for those not clearly categorized as high-risk. Experts emphasize the potential negative impact on vaccine distribution and individual health choices.
But the FDA framework urges companies conduct large, lengthy studies before tweaked vaccines can be approved for healthier people.
"Is the pharmacist going to determine if you're in a high-risk group?" asked Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia. "The only thing that can come of this will make vaccines less insurable and less available."
Collection
[
|
...
]